117 related articles for article (PubMed ID: 16814861)
1. Absence of renal lesions in C57BL/KaLwRij mice with advanced myeloma due to 5T2MM cells.
Libouban H; Onno C; Pascaretti-Grizon F; Gallois Y; Moreau MF; Baslé MF; Chappard D
Leuk Res; 2006 Nov; 30(11):1371-5. PubMed ID: 16814861
[TBL] [Abstract][Full Text] [Related]
2. Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse.
Libouban H; Moreau MF; Baslé MF; Bataille R; Chappard D
Biochem Biophys Res Commun; 2004 Apr; 316(3):859-66. PubMed ID: 15033480
[TBL] [Abstract][Full Text] [Related]
3. Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.
Asosingh K; Willems A; Van Riet I; Van Camp B; Vanderkerken K
Cancer Res; 2003 Jun; 63(12):3019-20. PubMed ID: 12810619
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
[TBL] [Abstract][Full Text] [Related]
7. The 5T2MM murine model of multiple myeloma: maintenance and analysis.
Vanderkerken K; Asosingh K; Willems A; De Raeve H; Couck P; Gorus F; Croucher P; Van Camp B
Methods Mol Med; 2005; 113():191-205. PubMed ID: 15968104
[TBL] [Abstract][Full Text] [Related]
8. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse.
Vanderkerken K; De Greef C; Asosingh K; Arteta B; De Veerman M; Vande Broek I; Van Riet I; Kobayashi M; Smedsrod B; Van Camp B
Br J Cancer; 2000 Feb; 82(4):953-9. PubMed ID: 10732771
[TBL] [Abstract][Full Text] [Related]
9. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma.
Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
Exp Hematol; 2004 Nov; 32(11):1064-72. PubMed ID: 15539084
[TBL] [Abstract][Full Text] [Related]
10. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
11. Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model.
Libouban H; Moreau MF; Baslé MF; Bataille R; Chappard D
Bone; 2003 Sep; 33(3):283-92. PubMed ID: 13678768
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.
Van Valckenborgh E; Croucher PI; De Raeve H; Carron C; De Leenheer E; Blacher S; Devy L; Noël A; De Bruyne E; Asosingh K; Van Riet I; Van Camp B; Vanderkerken K
Am J Pathol; 2004 Sep; 165(3):869-78. PubMed ID: 15331411
[TBL] [Abstract][Full Text] [Related]
13. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
14. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
[TBL] [Abstract][Full Text] [Related]
15. [Experimental animal models of multiple myeloma].
Miyakawa Y
Nihon Rinsho; 2007 Dec; 65(12):2211-7. PubMed ID: 18069262
[TBL] [Abstract][Full Text] [Related]
16. Mouse plasmacytoma: an experimental model of human multiple myeloma.
Gadó K; Silva S; Pálóczi K; Domján G; Falus A
Haematologica; 2001 Mar; 86(3):227-36. PubMed ID: 11255268
[TBL] [Abstract][Full Text] [Related]
17. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
Asosingh K; De Raeve H; de Ridder M; Storme GA; Willems A; Van Riet I; Van Camp B; Vanderkerken K
Haematologica; 2005 Jun; 90(6):810-7. PubMed ID: 15951294
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis.
Asosingh K; De Raeve H; Van Riet I; Van Camp B; Vanderkerken K
Blood; 2003 Apr; 101(8):3136-41. PubMed ID: 12480692
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma and related disorders. Lessons from an animal model.
Radl J
Pathol Biol (Paris); 1999 Feb; 47(2):109-14. PubMed ID: 10192877
[TBL] [Abstract][Full Text] [Related]
20. Altered bone microarchitecture and gene expression profile due to calcium deficiency in a mouse model of myeloma.
Libouban H; Chappard D
Micron; 2017 May; 96():77-85. PubMed ID: 28273524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
